Form 4 for PTGX Protagonist Therapeutics, Inc
Accepted 2026-06-25 16:10:30 ET · period of report 2026-06-23 · accession 0001104659-26-077761 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-06-25 16:10 | 2026-06-23 | PTGX | Waddill William D. | Dir | M - OptEx | $16.54 | +9,000 | 16.8K | +115% | +$148.9K |
| DT | 2026-06-25 16:10 | 2026-06-23 | PTGX | Waddill William D. | Dir | S - Sale+OE | $117.94 | -9,000 | 7,825 | -53% | -$1.06M |
| DT | 2026-06-25 16:10 | 2026-06-23 | PTGX | Waddill William D. | Dir | M - OptEx | $0.00 | -9,000 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-23 | M | A | 9,000 | $16.54 | 16,825 | D | — | — | (F1) The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026. |
| 2 | Common | Common Stock | 2026-06-23 | S | D | 9,000 | $117.94 | 7,825 | D | — | — | (F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $117.00 to $119.07. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 3 | Derivative | Stock Option (right to buy) | 2026-06-23 | M | D | 9,000 | $0.00 | 0 | D | $16.54 · — to 2030-05-27 | 9,000 Common Stock | (F3) These stock options are fully vested. |